Steroids having 7-oxygen and 17-heteroaryl substitution-2
US9102702B2 · kind B2 · utility
0Cited by
12References
14Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 16, 2013 |
| Grant date | Aug 11, 2015 |
| Priority date | — |
| Expiry date | Apr 15, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J41/0011
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β,7β-dihydroxy-17-(3-pyridyl)-androst-5,16-diene and other androst-5,16-diene compounds substituted at the 17-position with a heterocycle moiety and at the 3- and 7-positions with a hydroxyl, ester, ether or other disclosed moiety.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.